The companies in question, Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, are recalling seizure treatments, ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Sun Pharmaceutical Industries Ltd. 524715 shares inched down 0.26% to 1,609.90 Indian rupees Friday, on what proved to be an all-around poor trading session for the stock market, with the BSE ...

Sun Pharma is a top-ranked Indian pharmaceutical firm. The company’s stock has been continuously in the news lately for walking on the thin line of marketplace volatility, governmental regulations, ...

Market rally today: Stocks such as Asian Paints, NTPC, Reliance Industries, Tata Steel, Bajaj Finserv, HUL, Sun Pharma, Adani Ports, Axis Bank, TCS, Titan, Bajaj Finance and HCL Technologies were ...

Sun Pharma share price is Rs 117.48 with a 4.88% gain as of 11.45 am on 4 March 2025. It is a key player in the Indian healthcare industry. The company’s stock has shown significant growth in the past ...

Sun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutide in the next four to five years, said Managing Director ...

Mumbai: Pharma major, Sun Pharmaceutical, is gearing up to introduce its experimental anti-obesity and type 2 diabetes medicine in the next four to five years, Dilip Shanghvi, Managing Director of the ...

Compared to US generics, Sun Pharmaceutical’s specialty portfolio could be more impacted. This will result from the existing higher price points that could make it more challenging to pass on ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 shed 3.26% to 1,593.90 Indian rupees Friday, on what proved to be an all-around dismal trading session for the stock market, with the BSE SENSEX ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...